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Glioblastoma (GBM) is the most 
frequent primary tumor of the brain 
in adults. The median survival of 
GBM patients is 14.6 mo,1 despite 
aggressive multimodal therapy. Thus, 
there is an urgent need for novel 
therapies for the treatment of GBM. 
One promising approach in this sense 
is represented by approaches that target 
functionally validated tumor-associated 
antigens (TAAs). Chondroitin sulfate 
proteoglycan 4 (CSPG4, best known as 
NG2) is involved in several processes 
that favor GBM progression and high 
NG2 expression levels have been shown 
to negatively impact disease outcome.2-5 
As a proteoglycan on the cells surface, 
NG2 is amenable to antibody-based 
immunotherapy.
Although the immunoprivileged 
status of the nascent brain has been 
contested, there is a general consensus 
that GBM establishes multiple, 
coordinated mechanisms of escape from 
immunosurveillance,6 both de novo and 
as result of treatment. GBM cells express 
high levels of MHC class I molecules, 
that are ligands for inhibitory killer 
immunoglobulin-like receptors (KIRs), 
thus inhibiting the antineoplastic activity 
of natural killer (NK) cells. In the GBM 
microenvironment, the cytokine balance 
is skewed toward the elicitation of anti-
inflammatory T
H
2 responses and cancer 
cells mainly recruit immune cells with 
immunosuppressive properties. Although 
NK cells are not abundant within GBM 
lesions, representing 2.11 ± 0.54% of all 
lymphocytes, they exhibit the unusual 
CD56dimCD16- phenotype6. Moreover, 
GBM-infiltrating NK cells generally 
expressed activating killer cell lectin-like 
receptor subfamily K, member 1 (KLRK1, 
best known as NKG2D) receptors, which 
recognize stress ligands expressed by 
malignant cells.6 Pellegata and colleagues 
observed an increase in circulating, 
interferon γ (IFNγ)-producing NK cells 
that was associated with improved survival 
in GBM patients subjected to dendritic 
cell-based vaccination.7 Thus, anticancer 
treatments may activate endogenous 
NK cells against GBM. Taken together, 
these findings suggest that adoptively 
transferred, allogeneic NK cells may 
constitute a therapeutic option for GBM 
patients. Nevertheless, the therapeutic 
potential of purified NK cells against solid 
tumors has not been fully explored yet.
We have recently demonstrated that 
combining activated NK cells with a 
monoclonal antibody targeting NG2 
(mAb9.2.27) inhibits tumor growth 
and prolongs the survival of GBM-
bearing rats.8 The administration of 
NK cells plus mAb9.2.27 resulted in 
the recruitment to neoplastic lesions 
of pro-inflammatory ED1+CCR2low 
macrophages via the choroid plexus and 
blood vessels (Fig. 1). These macrophages 
differentiated into and/or drove the 
differentiation of ED1+ED2lowMHCIIhigh 
microglial cells that exerted robust 
cytotoxic effects against GBM cells. The 
depletion of ED1+CCR2low macrophages 
abrogated the therapeutic effect of NK 
cells plus mAb9.2.27 while promoting 
the accumulation of tumor-associated 
macrophages (TAMs) exhibiting an 
ED2+CCR2high anti-inflammatory 
phenotype as well as the differentiation 
of ED2high microglial cells that promoted 
GBM survival ex vivo.8 Remarkably, 
mAb9.2.27 reversed the tumor-promoting 
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Glioblastoma is a deadly brain cancer with limited treatment options. Targeting chondroitin sulfate proteoglycan 4 
(CsPG4, best known as NG2) with the monoclonal antibody mab9.2.27 and activated natural killer (NK) cells abrogated 
the tumor growth and prolonged the survival of glioblastoma-bearing animals by favoring the establishment of a pro-
inflammatory microenvironment. The combination of NK cells and mab9.2.27 recruited eD1+CCr2low macrophages that 
stimulated eD1+eD2lowMhCIIhigh microglial cells to exert robust cytotoxicity. Our findings demonstrate the therapeutic 
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effects of TAMs derived from a GBM 
biopsy or tumor xenografts. However, 
the ability of NK cells to kill GBM 
cells was not augmented by mAb9.2.27 
in vitro, indicating that the major role 
of NK cells in this setting is to secrete 




including IFNγ and tumor necrosis factor 
α (TNFα) upon exposure to GBM cells 
in vitro. Of note, the amounts of IFNγ 
and TNFα were increased in the cerebral 
spinal fluid of rats receiving NK cells plus 
mAb9.2.27, whereas the levels of other 
(immunosuppressive) cytokines such as 
interleukin (IL)-10, IL-6, and IL-1β were 
diminished. IFNγ increased the cytotoxic 
activity of the microglia against GBM 
cells in vitro. The synergistic interaction 
between NK cells and mAb9.2.27 might 
therefore originate from the combined 
effects of NK cell-derived IFNγ and 
mAb9.2.27 on the cytotoxic activity of 
microglial cells.
Our study did not elucidate the 
molecular mechanisms mediating 
the conversion of TAMs from tumor-
supporting ED2highCCR2high cells to 
ED1+ED2lowCCR2low cells exhibiting 
robust pro-inflammatory activity. This 
process may be regulated by miR-124, 
which has previously been shown to 
regulate the activation of microglial cells 
and macrophages in the central nervous 
system.9 It is therefore conceivable that the 
pro-inflammatory environment established 
by NK cells plus mAb9.2.27 modulates 
miR-124, promoting the activation of 
macrophages and microglial cells as well as 
their maintenance in a classically activated 
phenotype.
Our findings support the notion that 
the immunomodulation properties of 
NK cells, and notably (1) their ability to 
secrete pro-inflammatory cytokines, and 
(2) their capacity to influence the activity 
of the microglia and macrophages, may 
be exploited to boost the efficacy of 
passive immunotherapies targeting 
validated TAAs. One novelty of our 
approach related to the use of purified 
NK cells for the treatment of GBM, as 
previous attempts near-to-invariably 
employed autologous lymphokine 
activated killer (LAK) cells, which 
are a mixture of NK and T cells. The 
T-cell component of LAKs may actually 
Figure 1. adoptively transferred natural killer cells as initiators of glioblastoma regression. The intracranial administration of activated natural killer (NK) 
cells promotes cellular-dependent cytotoxicity against glioblastoma (GBM) (A) The NK cell-GBM cell interaction leads to the secretion of interferon γ 
(IFNγ) and tumor necrosis factor α (TNFα) by NK cells, in vitro and in vivo (B) IFNγ and TNFα can activate the resting microglia and/or anti-inflammatory 
tumor-associated macrophages (TaMs) to promote the establishment of pro-inflammatory conditions, ex vivo. such a pro-inflammatory environment 
is maintained by NK cells, which kill anti-inflammatory microglial cells (C) activated microglial cells and/or macrophages mediate natural as well as 
antibody-dependent cytotoxic functions, for instance upon the binding of mab9.2.27 to NG2+ GBM cells (D) Moreover, mab9.2.27 inhibits tumor growth 






































generate immunosuppressive regulatory 
T cells (Tregs), which would limit the 
therapeutic efficacy of such an approach.
The use of mAb9.2.27 as a standalone 
therapeutic intervention induced 
temporary tumor regressions, presumably 
due to the immunoediting of NG2-
expressing cells. Thus, simultaneously 
using monoclonal antibodies that are 
specific for several TAAs might reduce the 
selection of antigen loss tumor variants. 
Nevertheless, combining mAb9.2.27 with 
NK cells converted the tumor-promoting, 
anti-inflammatory microenvironment into 
a setting that allowed for therapeutically 
relevant tumor-specific immune 
responses. The selection of donors with 
NK cells expressing particular activating 
KIRs cognate to the MHCligands 
expressed by the patient GBM cells might 
further enhance the therapeutic potency 
of NK cells against GBM. However since 
NK cells may induce thrombocytopenia, 
and activated microglia are implicated in 
several neurological diseases, the safety, 
tolerable doses and duration of such a 
therapeutic approach requires stringent 
evaluations. Although it is desirable to 
study heterogeneous, patient-derived 
GBMs that pose significant therapeutic 
challenges, the role of Tregs might have 
been largely underestimated in studies 
relying on immunocompromised models. 
As NG2 is expressed on both malignant 
and angiogenic pericytes, humanized and/
or bispecific monoclonal antibodies that 
recognize NG2 epitopes on both these 
cell compartments may induce antibody-
dependent cell-mediated cytotoxicity 
(and hence mediate tumor destruction) 
more efficiently than molecules targeting 
either compartment alone. Furthermore, 
mAb9.2.27 may render cancer cells 
more susceptible to adjuvant chemo- 
and radiotherapy, as we have previously 
demonstrated that NG2 signaling 
augments chemo and radioresistance in 
GBM cells.4,5 Moreover, the therapeutic 
potential of NK cells might be further 
enhanced by the co-administration of 
multiple agents, such as the proteasome 
inhibitor bortezomib, which not only 
sensitized GBM cells to death receptor-
dependent apoptosis, but also stimulates 
the expression of stress-induced ligands. 
Additional NK cell-stimulatory agents 
include ligands for activatory receptors, 
anti-KIR antibodies, Toll-like receptor 
ligands and CpG oligodeoxynucleotides.10 
In summary, NK cells plus mAb9.2.27 
converted the anti-inflammatory 
GBM microenvironment into a pro-
inflammatory one dominated by M1-like 
macrophages and microglial cells that 
mediated tumor rejection. Our findings 
demonstrate the potential of targeting the 
tumor microenvironment as a means to 
stimulate endogenous immune responses 
and exert therapeutic effects against GBM.
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